rome and Foot-Ulcer

The aim of this study is to analyze the effects of peripheral blood mononuclear cells (PBMNCs) therapy in diabetic patients with critical limb ischemia (CLI), with particular regard to its application, as adjuvant therapy in patients underwent endovascular revascularization.. Fifty diabetic patients affected by CLI were enrolled. All patients underwent PBMNCs therapy. Thirty-two patients underwent PBMNCs therapy associated with endovascular revascularization (adjuvant therapy group). In 18 patients, who were considered nonrevascularizable or underwent unsuccessful revascularization, regenerative therapy with PBMNCs was performed as the therapeutic choice (PBMNCs therapy group).. The role of cellular therapy with PBMNCs is decisive in the patients that are not susceptible to revascularization. In diabetic patients with CLI and healing resistant ulcers, the adjuvant PBMNCs therapy could represent a valid therapeutic option.

Topics: Aged; Aged, 80 and over; Amputation, Surgical; Critical Illness; Disease Progression; Endovascular Procedures; Female; Foot Ulcer; Humans; Ischemia; Leukocytes, Mononuclear; Limb Salvage; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Recovery of Function; Risk Factors; Rome; Time Factors; Treatment Outcome; Wound Healing